Dr. Muzamil Majid Khan, a scientist from Hanjiwera Bala, Baramulla, has identified dextromethorphan, a common cough suppressant, as a potential treatment for lung fibrosis, a life-threatening condition with no cure.
Published in the December 2024 issue of Science Translational Medicine, the study reveals how the drug inhibits collagen buildup, reducing scarring in lung tissues.
The findings, validated through advanced techniques like proteomics and microscopy, showed promising results in human lung cells, 3D-cultured tissues, and mouse models.
Dr. Khan, based at EMBL Heidelberg in Germany, collaborated with leading research centers to advance the discovery toward phase II clinical trials. “Hard work never goes in vain,” he said, encouraging aspiring scientists in Kashmir to persevere.
Lung fibrosis, caused by excessive scarring in the lungs, affects millions globally, leading to breathing difficulties and organ failure. Risk factors include environmental pollutants, chemotherapy, and autoimmune disorders.
Dr. Khan’s journey began in local schools before earning his Bachelor’s degree from SP College, Srinagar, and a Ph.D. from the University of Heidelberg.
He credits a junior research stint under Prof. Obaid Siddiqi at NCBS, Bangalore, for shaping his career.
With this breakthrough, Dr. Khan has not only offered hope to patients worldwide but also inspired young researchers from Kashmir to pursue their scientific ambitions.